BSE Fundamental Analysis - Balance Sheet & Share Holding Pattern

FREDUNPHARMACEUTICALS01 Jan 1900

₹

0.00 (0.00%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in

FREDUNPHARMACEUTICALS01 Jan 1900

₹

0.00 (0.00%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
24-May-2023	D	Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, May 24, 2023 at 04.00 p.m. has inter-alia, considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended March 31, 2023 along with Statement of Assets and Liabilities and Cash Flow Statement as on that date. Enclosed are: a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Recommended Final Dividend at 7% per Equity Share having Face Value of Rs. 10/- each for the Financial Year 2022-23 subject to the approval of the Shareholders at the ensuing 36T Annual General Meeting of the Company;	22-Sep-2023
29-Jun-2021	D	The Board of Directors of the Company at its meeting today i.e. 28th June, 2021 has recommended Dividend of Rs. 0.7/- per share of Rs. 10 each (7 %) for the financial year ended 31st March, 2021 subject to approval of the Shareholders at the ensuing Annual General Meeting of the Company.	16-Sep-2021
11-Jun-2019	D	The Board in its meeting had considered and approved the Dividend of Rs. 0.60/- per Rs.10/- Equity Share of the Company. We would like to inform you that the 32nd Annual General Meeting ('AGM') of the Company is scheduled to be held on Tuesday, September 24, 2019 at 09:00 A.M. at Ramee Guest Line Hotel - Dadar Plot No. 3, Kohinoor Road, Dadar, Mumbai - 400 014. The cut-off date for entitlement to Dividend as declared by the Company at the rate of 6.5% shall be Tuesday, September 17, 2019. (As Per BSE Announcement Dated on 22/07/2019)	16-Sep-2019
19-Jun-2018	D	Fredun Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 18, 2018, inter alia, have considered and approved the following: - Recommended Final Dividend @ 6% i.e., Rs. 0.60/- per Equity Share having face value of Rs. 10/- each for the Financial Year 2017-18; subject to the Approval of the Shareholders at the ensuing Annual General Meeting of the Company.	18-Sep-2018
30-May-2017	D	Fredun Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2017, inter alia, has transacted the following: - Final Dividend at the rate of 6% to Equity Shareholders was approved by the Board and decided to be proposed for Shareholders approval at the upcoming Annual General Meeting.	20-Sep-2017
02-Apr-2016	D	Fredun Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 31, 2016, have decided to presently cancel the matter of issuing the Equity shares of the Company to the Investors under the Preferential Guidelines. Further, The Board of Directors of the Company at their meeting held on March 31, 2016 have declared an Interim Dividend of 0.60 paise (6%) per share for the year ending March 31, 2016.	11-Apr-2016
24-Apr-2024	BC	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2024 inter alia to consider and approve Notice is hereby given pursuant to R	07-May-2024
15-Apr-2024	BC	Allotment of 20,000 Equity Shares to Non-Promoter upon conversion of Warrants into Equity Shares	15-Apr-2024
22-Mar-2024	BC	This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotmen	22-Mar-2024
13-Mar-2024	BC	Trading members of the Exchange are hereby informed that the under mentioned new securities of Fredun Pharmaceuticals Limited (Scrip Code - 539730) are listed and permitted to trade on the Exchange w	14-Mar-2024
05-Feb-2024	BC	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve To discuss consider and approve Una	14-Feb-2024

Announcement Date24-May-2023

Ex Dividend Date22-Sep-2023

Dividend(%)7

Announcement Date29-Jun-2021

Ex Dividend Date16-Sep-2021

Dividend(%)7

Announcement Date11-Jun-2019

Ex Dividend Date16-Sep-2019

Dividend(%)6

Announcement Date19-Jun-2018

Ex Dividend Date18-Sep-2018

Dividend(%)6

Announcement Date30-May-2017

Ex Dividend Date20-Sep-2017

Dividend(%)6

Announcement Date02-Apr-2016

Ex Dividend Date11-Apr-2016

Dividend(%)6

No Rights has been declared by FREDUNPHARMACEUTICALS

Book Closure

Record Date	Split Date	Purpose
07-May-2024	-	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2024 inter alia to consider and approve Notice is hereby given pursuant to R
15-Apr-2024	-	Allotment of 20,000 Equity Shares to Non-Promoter upon conversion of Warrants into Equity Shares
22-Mar-2024	-	This is to inform you that the Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on September 23, 2022, has done allotmen
14-Mar-2024	-	Trading members of the Exchange are hereby informed that the under mentioned new securities of Fredun Pharmaceuticals Limited (Scrip Code - 539730) are listed and permitted to trade on the Exchange w
14-Feb-2024	-	Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve To discuss consider and approve Una

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Lupin Ltd ₹1,654.75(+7.10/0.43%)	1,654.75	+7.10	75,415.25	133.18	36.60	3.91
Ipca Laboratories Ltd ₹1,337.70(-13.30/-0.98%)	1,337.70	-13.30	33,938.01	88.94	61.57	5.46
J B Chemicals & Pharmaceuticals Ltd ₹1,889.90(+4.30/0.23%)	1,889.90	+4.30	29,330.27	80.31	57.90	10.92
Sanofi India Ltd ₹8,624.25(-53.50/-0.62%)	8,624.25	-53.50	19,861.65	59.17	33.61	19.54
IOL Chemicals & Pharmaceuticals Ltd ₹395.55(+3.25/0.83%)	395.55	+3.25	2,322.10	-0.40	13.44	1.46

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	86.65	81.48	61.23	79.73	77.65	68.84
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	86.65	81.48	61.23	79.73	77.65	68.84
Other Operating Income	0.35	0.50	0.82	0.08	0.31	1.48
Other Income	0.00	0.00	0.00	0.00	0.00	0.00
Total Income	87.01	81.99	62.05	79.80	77.96	70.32
Total Expenditure	76.49	72.38	54.44	67.54	70.65	63.53
PBIDT	10.52	9.61	7.61	12.26	7.31	6.80
Interest	3.77	2.90	2.61	3.55	1.95	1.86
PBDT	6.75	6.71	5.00	8.71	5.35	4.94
Depreciation	0.99	0.94	0.92	0.70	0.74	0.72
Tax	1.54	1.83	1.68	4.12	1.16	1.06
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
Reported Profit After Tax	4.22	3.94	2.40	3.89	3.46	3.15
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	4.22	3.94	2.40	3.89	3.46	3.15

EPS (Unit Curr.)	8.99	8.40	5.24	8.59	7.66	7.11
EPS (Adj) (Unit Curr.)	8.99	8.40	5.24	8.59	7.66	7.11
Calculated EPS (Unit Curr.)	8.99	8.40	5.24	8.59	7.66	7.11
Calculated EPS (Adj) (Unit Curr.)	8.99	8.40	5.24	8.59	7.66	7.11
Calculated EPS (Ann.) (Unit Curr.)	35.95	33.61	20.98	34.34	30.63	28.45
Calculated EPS (Adj) (Ann.) (Unit Curr.)	35.95	33.61	20.98	34.34	30.63	28.45
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	4.70	4.68	4.58	4.53	4.51	4.43
Reserve & Surplus	0.00	0.00	0.00	91.84	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	2309885.00	2272745.00	2259527.00	22420027.00	2180034.00
Public Shareholding (% in Equity)	0.00	49.31	49.62	49.85	49.66	48.96

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	2374277.00	2307377.00	2272745.00	2272745.00	2272745.00
Non Encumbered - % in Total Promoters Holding	0.00	100.00	100.00	100.00	100.00	100.00
Non Encumbered - % in Total Equity	0.00	50.69	50.38	50.15	50.34	51.04

PBIDTM(%)	12.14	11.79	12.43	15.38	9.41	9.88
PBDTM(%)	7.79	8.24	8.17	10.92	6.89	7.18
PATM(%)	4.87	4.84	3.92	4.88	4.46	4.58

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	4.53	4.43	3.99	3.99	3.99	3.43
Reserves Total	83.52	63.42	39.08	37.33	35.00	18.74
Equity Share Warrants	8.33	0.21	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	96.38	68.06	43.07	41.32	38.99	22.17
Secured Loans	0.00	0.00	0.00	0.00	0.00	0.00
Unsecured Loans	86.53	52.76	39.64	34.90	19.27	9.90
Total Debt	86.53	52.76	39.64	34.90	19.27	9.90
Total Liabilities	182.91	120.82	82.71	76.22	58.26	32.07
APPLICATION OF FUNDS :
Gross Block	51.54	42.14	37.99	36.61	35.11	25.00
Less : Accumulated Depreciation	12.61	9.80	7.64	5.64	3.76	8.71
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	38.93	32.34	30.35	30.97	31.35	16.29
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	0.00	0.00	0.00	11.15
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.31	0.06	0.06	0.05	0.01	0.00
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	150.12	46.46	67.57	50.46	40.78	18.43
Sundry Debtors	34.56	90.27	41.08	38.97	17.78	15.26
Cash and Bank	3.44	2.07	1.13	3.06	1.47	1.45
Loans and Advances	27.78	13.79	20.25	16.78	12.49	16.34
Total Current Assets	215.90	152.59	130.02	109.27	72.52	51.48
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	64.28	60.24	74.80	60.01	34.59	40.25
Provisions	4.29	2.79	1.13	2.57	10.18	2.89
Total Current Liabilities	68.57	63.03	75.92	62.58	44.78	43.14
Net Current Assets	147.33	89.57	54.10	46.69	27.74	8.34
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liability	3.84	1.43	1.38	0.94	0.79	0.81
Net Deferred Tax	-3.84	-1.43	-1.38	-0.94	-0.79	-0.81
Total Assets	182.73	120.54	83.13	76.77	58.31	34.96
Contingent Liabilities	0.00	0.00	0.00	0.00	0.00	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	2.07	1.13	3.06	1.47	1.45
Net Cash from Operating Activities	-14.41	-2.38	0.17	-10.64	0.84
Net Cash Used In Investing Activities	-9.40	-4.14	-1.39	-1.49	-5.25
Net Cash Used In Financing Activities	25.18	7.47	-0.71	13.73	4.43
Net Inc./Dec In Cash And Cash Equivalents	1.36	0.94	-1.93	1.59	0.01
Cash And Cash Equivalents At End Of The Year	3.44	2.07	1.13	3.06	1.47

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

48.92%

FII Shareholding

0.00%

DII Shareholding

1.59%

Public Shareholding

49.49%

**Promoter pledged shareholding 48.92%

About Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 422.07 crores. It has reported a sales of Rs. 86.65 crores and a net profit of Rs. 4.22 crores for the quarter ended December 2018. The company management includes Daulat N Medhora, Daulat N Medhora,Nariman B Medhora,Aspi N Raimalwala,Fredun N Medhora,Rohinton Kanga,Jinkal Shah,Daisy Dsouza (Fredun Pharmaceuticals Ltd) among others.

Chairman

Daulat N Medhora

Registered office

26 Manoj Industrial Premises,G D Ambedkar Marg Wadala,Mumbai,Maharashtra,400031

FAX :

Background

Incorporation Year1987

Face Value₹10

Market Lot1

How to buy shares on nse?

To buy shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the share price today?

The shares price on nse is Rs.0 today.

What is the market cap of shares on ?

The company has a market capitalization of Rs.0.00Cr

What is the PE & PB ratio of shares ?

PE is 0 and PB is 0

What is the 52 Week High and Low of shares?

stock price high: Rs.0 stock price low: Rs.0